Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
复制标题
DOI：
10.1182/blood-2009-01-201988
复制
发表时间：
2009-06-04
期刊：
影响因子：
20.3
通讯作者：
Levy, Ronald
中科院分区：
文献类型：
--
作者：
Ai, Weiyun Z.;Tibshirani, Robert;Levy, Ronald
先前的研究表明，疫苗接种诱导的肿瘤特异性免疫反应与滤泡性淋巴瘤患者的优异临床结果相关。在这里，我们研究了这种正相关性是否延伸到总生存期 (OS)。我们分析了 91 名未经治疗的患者，他们接受 CVP 化疗（环磷酰胺、长春新碱和泼尼松），然后接种独特型疫苗。独特型蛋白质通过杂交瘤方法或通过在哺乳动物或基于植物的表达系统中表达重组独特型编码序列来产生。我们发现，实现 CVP 完全缓解/未确认完全缓解 (CR/CRu) 和产生抗独特型抗体是两个独立因素，每个因素都与 10 年较长 OS 相关（有或没有 CR/CRu 时为 89% vs 68%，P = .024；有或没有肿瘤特异性抗体产生时为 90% vs 69%；P = .027）。在接受杂交瘤产生的疫苗的患者子集中，我们发现抗独特型的产生与优越的 OS 高度相关（P < .002）；即使在对 CVP 部分缓解 (PR) 的患者中也是如此 (P < .001)。 （血。2009；113：5743-5746）
Previous studies demonstrated that vaccination-induced tumor-specific immune response is associated with superior clinical outcome in patients with follicular lymphoma. Here, we investigated whether this positive correlation extends to overall survival (OS). We analyzed 91 untreated patients who received CVP chemotherapy (cyclophosphamide, vincristine, and prednisone) followed by idiotype vaccination. Idiotype proteins were produced either by the hybridoma method or by expression of recombinant idiotype-encoding sequences in mammalian or plant-based expression systems. We found that achieving a complete response/ complete response unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that each correlated with longer OS at 10 years (89% vs 68% with or without a CR/CRu, P = .024; 90% vs 69% with or without tumor-specific antibody production; P = .027). In the subset of patients who received hybridoma-generated vaccines, we found that anti-idiotype productionwaseven more highly associated with superior OS (P < .002); this was the case even in patients with a partial response (PR) to CVP (P < .001). (Blood. 2009; 113: 5743-5746)